Biosimilars Europe: Looking Ahead Into the New European Landscape
Case studies from both Switzerland and Norway on strategic management and switching studies with two keynotes from Merck Group and the Norwegian Medicines Agency.
London, United Kingdom, July 03, 2016 --(PR.com)-- SMi are delighted to announce that both the Norwegian and Swiss markets will be represented at Biosimilars Europe when it returns to London for its 7th annual show on 29th and 30th September.
Will the UK’s withdrawal from the European Union also translate into an unravelling of its relations to the European Medicines Agency? Non-EU members like Norway still adhere to the EMA process and all of its rules and the Swiss regulatory agency, Swissmedic, which is separate from the EMA, still works alongside EMA and its agreements.*
In a Merck Group case study, Head of Biosimilars Strategy & Portfolio Management from Switzerland, Atanas Dimitrov, will review the unique characteristics of the biosimilar asset class by comparing lower risk vs original biologics, and in-licensing vs novel pharmaceuticals. Attendees will also receive strategic guidance on the organisational set-up for biosimiars.
This will be followed by a keynote address from The Norwegian medicines agency, who will explore the process of switching from biosimilars to biogenerics without EU regulations. Medical Director, Dr Steinar Madsen, will discuss the uptake of biosimilars in clinical practice with a focus on switching studies and clinical trials.
Further addresses looking into the future of Biosimilars in Europe include presentations from:
· Alan Sheppard, Principal, Global Generics and Biosimilars, IMS Helath
· Dr Duncan Emerton, Senior Director, Syndicated Insights & Analysis, First Word
· Dr Dominic Adair, Partner, Bristows LLP
The detailed agenda and full speaker line-up is available online at: www.biosimilars-europe.com/prcom
Biosimilars Europe 2016
7th Annual Conference: 29th & 30th Sept | Interactive Workshops: 28th Sept
Holiday Inn Kensington Forum, London UK
Proudly Sponsored by: Abzena and Schwegman Lundberg Woessner
For all media enquiries contact Teri Arri on Tel: +44 (0)20 7827 6162 / Email: tarri@smi-online.co.uk
To register for the conference, visit www.biosimilars-europe.com/prcom or contact Fateja Begum on Tel: +44 (0)20 7827 6184 / Email: fbegum@smi-online.co.uk
To sponsor, speak or exhibit at the conference, contact Alia Malick on Tel: +44 (0)20 7827 6168 / Email: amalick@smi-online.co.uk
About SMi Group
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
[Source: http://bit.ly/28ZCThx]
Will the UK’s withdrawal from the European Union also translate into an unravelling of its relations to the European Medicines Agency? Non-EU members like Norway still adhere to the EMA process and all of its rules and the Swiss regulatory agency, Swissmedic, which is separate from the EMA, still works alongside EMA and its agreements.*
In a Merck Group case study, Head of Biosimilars Strategy & Portfolio Management from Switzerland, Atanas Dimitrov, will review the unique characteristics of the biosimilar asset class by comparing lower risk vs original biologics, and in-licensing vs novel pharmaceuticals. Attendees will also receive strategic guidance on the organisational set-up for biosimiars.
This will be followed by a keynote address from The Norwegian medicines agency, who will explore the process of switching from biosimilars to biogenerics without EU regulations. Medical Director, Dr Steinar Madsen, will discuss the uptake of biosimilars in clinical practice with a focus on switching studies and clinical trials.
Further addresses looking into the future of Biosimilars in Europe include presentations from:
· Alan Sheppard, Principal, Global Generics and Biosimilars, IMS Helath
· Dr Duncan Emerton, Senior Director, Syndicated Insights & Analysis, First Word
· Dr Dominic Adair, Partner, Bristows LLP
The detailed agenda and full speaker line-up is available online at: www.biosimilars-europe.com/prcom
Biosimilars Europe 2016
7th Annual Conference: 29th & 30th Sept | Interactive Workshops: 28th Sept
Holiday Inn Kensington Forum, London UK
Proudly Sponsored by: Abzena and Schwegman Lundberg Woessner
For all media enquiries contact Teri Arri on Tel: +44 (0)20 7827 6162 / Email: tarri@smi-online.co.uk
To register for the conference, visit www.biosimilars-europe.com/prcom or contact Fateja Begum on Tel: +44 (0)20 7827 6184 / Email: fbegum@smi-online.co.uk
To sponsor, speak or exhibit at the conference, contact Alia Malick on Tel: +44 (0)20 7827 6168 / Email: amalick@smi-online.co.uk
About SMi Group
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
[Source: http://bit.ly/28ZCThx]
Contact
SMi Group
Terri Arri
+44 (0)20 7827 6162
www.biosimilars-europe.com/prcom
Terri Arri
+44 (0)20 7827 6162
www.biosimilars-europe.com/prcom
Contact
Categories